Source disclosure: February 12, 2026
Kidswell Bio Corporation [4584.T]
TOKYO, Feb 12 (Pulse News Wire) – Kidswell Bio Corporation (4584.T) reported an increase in extraordinary expenses due to bank borrowing fees amounting to ¥75 million, which will be recorded as operating expenses. Additionally, based on recent performance trends, the company revised its full-year consolidated earnings forecast upward for the fiscal year ending March 31, 2026.
The updated forecast shows: | Metric | Previous Estimate (A) | Revised Estimate (B) | Increase/(Decrease) (B-A) | |-----------------|------------------------------|----------------------------|---------------------------| | Revenue | ¥5.500 billion to ¥6 billion | ¥6.500 billion to ¥500 million | ¥~¥1 billion to ¥~¥700 million | | Operating Profit | ¥--¥600 million to ¥--¥300 million | ¥100 million to ¥500 million | ¥~[figure] million to ¥~[figure] million | The revision reflects improved visibility in manufacturing and delivery plans for key raw materials, along with adjustments in research and development costs. As a result, sales projections now exceed initial estimates made during the second quarter.
Kidswell Bio remains committed to ongoing discussions with stakeholders to refine forecasts further and will promptly disclose more detailed expectations once reasonable assumptions are established.
AI-translated content. 🟢 Confidence: High See terms •
Forecast revision — FY2026/3Forecast revised
| Metric | Prior | Revised | Change |
|---|---|---|---|
| Revenue | ¥5,500M | ¥6,500M | +18.2% |
| Op. profit | ¥-600M | ¥100M | |
| Net profit | n/a | n/a |
Source: TDNet filing · Figures in millions of yen